The North European SGA Study
Treatment with recombinant growth hormone in children born small for gestational age (SGA) without catch-up growth
An open multicenter study
Aim of study
To evaluate changes in short and long term growth, body composition and insulin sensitivity at different GH doses (low, high and IGF-I titrated dose).
300 short children born SGA aged 4-8.99 years (4-9.99 years in boys) from 7 European centres.
Year 2 and thereafter, patients randomized to receive:
Duration of treatment
Every 3 months:
At baseline, 1 yr and 3 yr:
At baseline and 2 yr:
Anders Juul, Copenhagen, Denmark (principal investigator)
If you require any help, please contact:
Randomisation service provided by: Sealed Envelope.com